Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSIST-1: Canfosfamide vs Doxil or Hycamtin in Platinum Refractory/Resistant Ovarian Cancer
NCT00057720Phase 3Completed
- Sponsor
- Telik, Inc.
- Start
- Jun 2003
- Primary completion
- Dec 2006
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of canfosfamide in ovarian cancer (2 arms), sponsored by Telik, Inc. Primary endpoint: Overall Survival. Started Jun 2003; status: completed.
02
Drugs
canfosfamide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00057720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057720.